What the research found

Researchers analysing population data found that people performing strength training for roughly 90–120 minutes per week showed a 13% reduction in all-cause mortality compared to those doing no resistance work. The benefit was most pronounced for cardiovascular and neurological causes of death. When strength training was combined with aerobic exercise, the protective effect increased substantially—associated with a 45% lower overall mortality risk in the groups studied.

The analysis appears to have drawn from existing epidemiological datasets rather than a controlled trial, meaning the researchers examined patterns in people who already had different exercise habits.

Why it matters for you

This sits squarely in the "dose" question many MyKine users wrestle with: how much lifting is enough? The 90–120 minute range maps cleanly onto accessible weekly protocols—two 45–60 minute sessions, or three 30–40 minute sessions. If you're logging resistance work in the app and tracking it against your other biomarkers, this suggests the volume sweet spot may be lower than some programming styles demand.

The cardiovascular and neurological benefits hint at systemic adaptations beyond muscle gain: improved vascular function, metabolic health, and potentially neuroprotection. For users monitoring markers like blood pressure, lipid panels, fasting glucose, or inflammatory markers, strength training at this dose may be doing more than the mirror shows.

The synergy with aerobic work also matters. If you're already running, cycling, or doing zone-2 cardio, adding or maintaining consistent resistance training appears to unlock disproportionate protection—not just additive benefit.

Caveats

  • Observational: People who strength train regularly differ in many unmeasured ways (diet, sleep, stress) from those who don't; causation isn't established.
  • Mortality data: Deaths from specific causes are rare events; the relative risk reductions are meaningful but the absolute risk change for any individual is harder to estimate.
  • Population-level result: Average benefit doesn't guarantee individual response; genetics, baseline fitness, and adherence all matter.
  • No dose–response detail: We don't know if 60 minutes is notably worse than 120, or if more is better—just that the 90–120 band showed benefit.